Coronavirus live news: India passes 20m cases; German plan to give more freedoms to fully vaccinated ‘unfair’ | World news
“Due to the Defense Production Act, we do not receive certain goods from the USA,” said CureVac boss Franz-Werner Haas to the weekly newspaper Der Spiegel.
The Defense Production Act is a decade-old US law that gives federal agencies the power to prioritize procurement contracts related to national defense. However, it has also been widely used in non-military crises such as natural disasters.
“We don’t get all of the materials we need,” he was quoted as saying.
“Sometimes we live from hand to mouth. That makes it difficult to build inventory, ”Haas said when asked how much the company could deliver over the summer months.
In contrast to the competing German vaccine developer BioNTech, which has entered into a partnership with the pharmaceutical giant Pfizer, CureVac has not teamed up with a US partner. BioNTech and Pfizer continue to grow global production and have not cited the Defense Production Act as an obstacle.
As the only major supply agreement with CureVac, the European Union received up to 405 million doses of the vaccine last November.
The biotech company has announced that it will apply for European approval in late May or early June.
Nasdaq-listed company CureVac, which is supported by investors Dietmar Hopp, GlaxoSmithKline and the federal government, has announced that it will produce up to 300 million doses of the vaccine by 2021 and up to 1 billion doses of the vaccine by 2022.